JNK (c-Jun N-terminal Kinase) Protein

JNK (c-Jun N-terminal kinase, also known as MAPK8) is a stress-activated serine/threonine protein kinase belonging to the MAPK family. It is activated by cellular stress, inflammatory cytokines, and excitotoxicity, playing complex and context-dependent roles in neuronal survival and death. JNK is particularly implicated in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders. ^{1Advances in JNK inhibitor development: therapeutic prospects in neurodegenerative diseases and fibrosis2025 · Trends in Pharmacological Sciences · PMID 40920304Open reference}

Pathway Diagram

flowchart TD
    JNK["JNK"]
    style JNK fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0
    Apoptosis["Apoptosis"]
    JNK -->|"activates"| Apoptosis
    Tumor["Tumor"]
    JNK -->|"activates"| Tumor
    Mapk["Mapk"]
    JNK -->|"activates"| Mapk
    Inflammation["Inflammation"]
    JNK -->|"activates"| Inflammation
    INFLAMMATION["INFLAMMATION"]
    JNK -->|"inhibits"| INFLAMMATION
    JNK -->|"inhibits"| Inflammation
    JNK -->|"inhibits"| Mapk
    JUN["JUN"]
    JNK -->|"activates"| JUN
    JUN -->|"activates"| JNK
    ERK["ERK"]
    ERK -->|"inhibits"| JNK
    ERK1["ERK1"]
    ERK1 -->|"activates"| JNK
    APOPTOSIS["APOPTOSIS"]
    APOPTOSIS -->|"activates"| JNK
    ROS["ROS"]
    ROS -->|"activates"| JNK
    C_JUN["C-JUN"]
    C_JUN -->|"activates"| JNK
    ERK -->|"activates"| JNK
    PI3K["PI3K"]
    PI3K -->|"activates"| JNK
    style Apoptosis fill:#5d4400,stroke:#ffd54f,color:#e0e0e0
    style Tumor fill:#ef5350,stroke:#ef5350,color:#e0e0e0
    style Mapk fill:#5d4400,stroke:#ffd54f,color:#e0e0e0
    style Inflammation fill:#ef5350,stroke:#ef5350,color:#e0e0e0
    style INFLAMMATION fill:#1b5e20,stroke:#81c784,color:#e0e0e0
    style JUN fill:#1b5e20,stroke:#81c784,color:#e0e0e0
    style ERK fill:#1b5e20,stroke:#81c784,color:#e0e0e0
    style ERK1 fill:#1b5e20,stroke:#81c784,color:#e0e0e0
    style APOPTOSIS fill:#1b5e20,stroke:#81c784,color:#e0e0e0
    style ROS fill:#1b5e20,stroke:#81c784,color:#e0e0e0
    style C_JUN fill:#1b5e20,stroke:#81c784,color:#e0e0e0
    style PI3K fill:#1b5e20,stroke:#81c784,color:#e0e0e0

Gene and Isoforms

JNK exists as three isoforms: JNK1 and JNK2 are ubiquitously expressed, while JNK3 is predominantly neuronal and is the major isoform implicated in neurodegeneration. ^{2Neuroprotective role of JNK inhibitors in neurodegenerative diseases2023 · Neuroscience and Biobehavioral Reviews · PMID 37253831Open reference}

Structure

JNK proteins share a central kinase domain flanked by N- and C-terminal regions. The kinase domain adopts a typical bilobal structure characteristic of protein kinases. JNK is activated by dual phosphorylation on a Thr-X-Tyr (TXY) motif within its activation loop, catalyzed by upstream MKK4 and MKK7 kinases. The JNK3 isoform contains a unique 30-amino acid C-terminal extension that may confer neuronal specificity. ^{3JNK-associated stellar photocoagulation in Alzheimer's disease2020 · Cellular and Molecular Neurobiology · PMID 31834567Open reference}

Normal Function

Activation Mechanisms

JNK is activated through a canonical three-tier kinase cascade:

1. Upstream activation: Stress signals (UV radiation, oxidative stress, inflammatory cytokines) activate MAPKKKs such as MEKK1, MLK3, and TAK1

2. Intermediate phosphorylation: MAPKKs (MKK4/MKK7) phosphorylate JNK on Thr183 and Tyr185

3. Downstream signaling: Activated JNK translocates to the nucleus and phosphorylates transcription factors

Key Targets

• c-Jun: Primary transcription factor substrate; phosphorylation at Ser63/Ser73 promotes AP-1-mediated gene transcription

• Bim (BCL2L11): Pro-apoptotic BH3-only protein; JNK-mediated phosphorylation activates Bim

• BAD: Pro-apoptotic protein; phosphorylation promotes cell death

• Tau: JNK phosphorylates tau at multiple sites including Ser396, Thr181, and Ser202 -- sites also targeted by other stress kinases in Alzheimer’s disease ^{4c-Jun N-terminal kinase signaling in tauopathies2023 · Frontiers in Aging Neuroscience · PMID 36910903Open reference}

• ATF2: Stress-responsive transcription factor

• Bcl-2: JNK can phosphorylate anti-apoptotic Bcl-2, reducing its protective function

Physiological Roles

In the healthy brain, JNK regulates:

• Stress response and cellular adaptation to environmental insults

• Neuronal development and differentiation

• Synaptic plasticity and dendritic spine morphology

• Regulation of neuronal excitability

Role in Alzheimer’s Disease

JNK is strongly activated in Alzheimer’s disease brains, particularly in regions vulnerable to neurodegeneration such as the hippocampus and prefrontal cortex. ^{5JNK pathway in amyloid-beta-induced neurotoxicity2023 · Molecular and Cellular Neuroscience · PMID 37598901Open reference}

Neuronal Death Pathways

• c-Jun activation: JNK-mediated phosphorylation of c-Jun promotes expression of pro-apoptotic genes

• Bim activation: JNK phosphorylates Bim, relieving it from inhibition by Bcl-2/Bcl-xL, leading to mitochondrial outer membrane permeabilization (MOMP)

• Caspase activation: JNK contributes to caspase-3 and caspase-9 activation through both intrinsic (mitochondrial) and extrinsic (death receptor) pathways

Tau Pathology

JNK directly phosphorylates tau at multiple pathological sites. In AD brains, p-JNK colocalizes with neurofibrillary tangles, and JNK activity correlates with Braak staging. JNK also phosphorylates the microtubule-associated protein tau (MAPT) gene promoter, potentially altering tau expression levels. ^{4c-Jun N-terminal kinase signaling in tauopathies2023 · Frontiers in Aging Neuroscience · PMID 36910903Open reference}

Amyloid-Beta Interactions

Aβ oligomers activate the JNK pathway through multiple mechanisms:

• Aβ binds to various neuronal receptors (e.g., NMDA receptors, RAGE) that trigger upstream kinase activation

• Aβ-induced oxidative stress activates MLK3-MKK4/7-JNK cascade

• JNK activation contributes to Aβ-induced synaptic dysfunction and spine loss

• Inhibition of JNK protects against Aβ-induced neuronal death in cultured neurons and animal models ^{5JNK pathway in amyloid-beta-induced neurotoxicity2023 · Molecular and Cellular Neuroscience · PMID 37598901Open reference}

Role in Parkinson’s Disease

JNK3 is the predominant isoform in dopaminergic neurons of the substantia nigra pars compacta and is implicated in Parkinson’s disease through multiple mechanisms. ^{6JNK pathway in Parkinson's disease: molecular mechanisms and therapeutic targets2021 · Molecular Neurobiology · PMID 33987958Open reference}

Dopaminergic Neuron Vulnerability

• Mitochondrial dysfunction: JNK is activated by mitochondrial stress and contributes to MPTP/MPTP model dopaminergic toxicity

• α-Synuclein aggregation: α-synuclein oligomers activate JNK; JNK activation in turn promotes α-synuclein aggregation and spread

• Inflammation: Microglial JNK activation drives production of pro-inflammatory cytokines (IL-1β, TNF-α) that damage dopaminergic neurons

Neuroprotection Studies

• JNK3 knockout mice show reduced dopaminergic neuron death in MPTP models

• Peptide inhibitors of JNK (e.g., D-JNKI1) protect against 6-OHDA and MPTP toxicity

• Small molecule JNK inhibitors (SP600125, JNK-IN-8) reduce neurodegeneration in PD animal models

Role in Other Neurodegenerative Disorders

Huntington’s Disease

• Mutant huntingtin protein activates JNK through aberrant protein interactions and transcriptional dysregulation

• JNK contributes to striatal neuron death through c-Jun activation and mitochondrial dysfunction

• JNK inhibition reduces toxicity in HD models

Amyotrophic Lateral Sclerosis (ALS)

• JNK is activated in motor neurons in ALS models and patient samples

• Both SOD1 and TDP-43 mutations activate the JNK pathway

• JNK inhibition delays disease onset and extends survival in SOD1 mouse models

Stroke and Traumatic Brain Injury

• Ischemia rapidly and strongly activates JNK in affected brain regions

• JNK contributes to both neuronal death and glial activation in stroke

• JNK inhibitors reduce infarct volume when administered within therapeutic windows

Therapeutic Targeting

Small Molecule Inhibitors

Clinical Status

JNK inhibitors have been tested in clinical trials for inflammatory diseases (rheumatoid arthritis, COPD) with acceptable safety profiles, establishing a foundation for neurodegenerative applications. However, JNK inhibitors have not yet reached Phase 2/3 trials for AD or PD. ^{1Advances in JNK inhibitor development: therapeutic prospects in neurodegenerative diseases and fibrosis2025 · Trends in Pharmacological Sciences · PMID 40920304Open reference}

Challenges

• Achieving CNS penetration with small molecule JNK inhibitors

• Isoform selectivity (targeting JNK3 over JNK1/2 to reduce peripheral toxicity)

• Timing of intervention -- JNK has both protective and destructive roles depending on context

• Biomarker development for patient selection

Protein Interactions

See Also

• Alzheimer’s Disease

• Parkinson’s Disease

• Huntington’s Disease

• Tau Protein

• Apoptosis Pathway

• MAPK Signaling Cascade